These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9836478)

  • 1. The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.
    Walton MI; Mitchell F; Aherne GW; Medlow CJ; Boyle FT; Jackman AL
    Br J Cancer; 1998 Dec; 78(11):1457-63. PubMed ID: 9836478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
    Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
    Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.
    Aherne GW; Hardcastle A; Ward E; Dobinson D; Crompton T; Valenti M; Brunton L; Jackman AL
    Clin Cancer Res; 2001 Sep; 7(9):2923-30. PubMed ID: 11555611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
    de Jonge MJ; Glimelius B; Verweij J; Van Groeningen C; Bonneterre J; de Vries EG; Culine S; Young J; Smith R; Droz J
    Anticancer Drugs; 2002 Jul; 13(6):645-53. PubMed ID: 12172511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor.
    Kobayashi H; Takemura Y; Miyachi H
    Cancer Chemother Pharmacol; 1998; 42(2):105-10. PubMed ID: 9654109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
    Plummer R; Rees C; Hughes A; Beale P; Highley M; Trigo J; Gokul S; Judson I; Calvert H; Jackman A; Mitchell F; Smith R; Douglass E
    Clin Cancer Res; 2003 Apr; 9(4):1313-22. PubMed ID: 12684399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
    Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
    Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
    de Jonge MJ; Punt CJ; Sparreboom A; Planting AS; Peters ME; van De Schraaf J; Jackman A; Smith R; de Mulder PH; Verweij J
    J Clin Oncol; 2002 Apr; 20(7):1923-31. PubMed ID: 11919253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folate-based thymidylate synthase inhibitors as anticancer drugs.
    Jackman AL; Calvert AH
    Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
    Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.
    Aherne GW; Ward E; Lawrence N; Dobinson D; Clarke SJ; Musgrove H; Sutcliffe F; Stephens T; Jackman AL
    Br J Cancer; 1998; 77(2):221-6. PubMed ID: 9460992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.
    Walton MI; Gibson W; Aherne GW; Lawrence N; Stephens TC; Smith MN; Jackman AL
    J Pharmacol Exp Ther; 1996 May; 277(2):909-16. PubMed ID: 8627573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.
    Webley SD; Hardcastle A; Ladner RD; Jackman AL; Aherne GW
    Br J Cancer; 2000 Sep; 83(6):792-9. PubMed ID: 10952785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
    Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
    Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZD9331: discovery to clinical development.
    Benepal TS; Judson I
    Anticancer Drugs; 2005 Jan; 16(1):1-9. PubMed ID: 15613898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase inhibitors.
    Touroutoglou N; Pazdur R
    Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
    Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
    Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.
    Jodrell DI; Newell DR; Morgan SE; Clinton S; Bensted JP; Hughes LR; Calvert AH
    Br J Cancer; 1991 Nov; 64(5):833-8. PubMed ID: 1931603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
    Rees C; Beale P; Trigo JM; Mitchell F; Jackman A; Smith R; Douglass E; Judson I
    Clin Cancer Res; 2003 Jun; 9(6):2049-55. PubMed ID: 12796367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.